Scleromyxedema with subcutaneous nodules: Successful treatment with thalidomide and intravenous immunoglobulin

Case Reports in Dermatology

Volumn 5, Issue 3, 2013, Pages 309-315

  Dolenc Voljc M ^a,b   Jurcic V ^b   Hocevar A ^a   Tomsic M ^a,b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Intravenous immunoglobulin; Monoclonal gammopathy; Mucinosis; Nodular mucinosis; Papular mucinosis; Scleromyxedema; Thalidomide

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE; MUCIN; PLASMA PROTEIN; THALIDOMIDE; COLLAGEN;

ADULT; ARM SWELLING; ARTHRALGIA; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPHAGIA; ELECTROMYOGRAPHY; FACE EDEMA; FATIGUE; FOLLOW UP; HAIR LOSS; HAND EDEMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERGAMMAGLOBULINEMIA; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; MYALGIA; MYOPATHY; NECK RASH; NEUROLOGIC EXAMINATION; PAPULAR RASH; PARESTHESIA; PHOTOELECTRIC PLETHYSMOGRAPHY; PRIORITY JOURNAL; REMISSION; SCLEROMYXEDEMA; SKIN INDURATION; SKIN PRURITUS; SUBCUTANEOUS NODULE; TREATMENT DURATION; COMPUTER ASSISTED TOMOGRAPHY; LOW DRUG DOSE; PARAPROTEINEMIA; PRURITUS;

EID: 84892974531     PISSN: None     EISSN: 16626567     Source Type: Journal    
DOI: 10.1159/000356469     Document Type: Article

References (27)

1. Rongioletti F, Rebora A: Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001;44:273-281.
2. Rongioletti F, Rebora A: Mucinoses; in Bolognia JL, Jorizzo JL, Schaffer JV (eds): Dermatology, ed 3. Philadelphia, Elsevier, 2012, pp 687-698.
3. Dinneen AM, Dicken CH: Scleromyxedema. J Am Acad Dermatol 1995;33:37-43.
4. Rongioletti F, Amantea A, Balus L, Rebora A: Cutaneous focal mucinosis associated with reticular erythematous mucinosis and scleromyxedema. J Am Acad Dermatol 1991;24:656-657.
5. Craig NM, Putterman AM, Roenigk RK, Wang TD, Roenigk HH: Multiple periorbital cutaneous myxomas progressing to scleromyxedema. J Am Acad Dermatol 1996;34:928-930.
6. Singh S, Kanwar AJ, Saikia UN: Scleromyxoedema with disseminated subcutaneous nodules: Rare presentation of an uncommon dermatosis. Clin Exp Dermatol 2012;38:36-39.
7. Rongioletti F, Merlo G, Cinotti E, Fausti V, Cozzani E, et al: Scleromyxedema: A multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol 2013;69:66-72.
8. Sroa N, Campbell S, Bechtel M: Intravenous immunoglobulin therapy for scleromyxedema: A case report and review of literature. J Drug Dermatol 2010;9:263-265.
9. Blum M, Wigley FM, Hummers LK: Scleromyxedema. A case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine 2008;87:10-20.
10. Caradonna S, Jacobe H: Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol 2004;140:277-280.
11. Kulczycki A, Nelson M, Eisen A, Heffernan M: Scleromyxoedema: Treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br J Dermatol 2003;149:1276-1281.
12. Gabriel SE, Perry HO, Oleson GB, Bowles CA: Scleromyxedema: A scleroderma-like disorder with systemic manifestations. Medicine 1988;67:58-65.
13. Wojas-Pelc A, Blaszczyk M, Gliska M, Jabloska S: Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins. J Eur Acad Dermatol Venereol 2005;19:462-465.
14. Manousaridis I, Loeser C, Goerdt S, Hassel JC: Managing scleromyxedema with intravenous immunoglobulin: Acute worsening of scleromyxedema with biclonal gammopathy. Acta Dermatoven APA 2010;19:15-19.
15. Kreuter A, Stücker M, Kolios AGA, Altmeyer P, Möllenhoff K: Skleromyxödem. Eine chronisch progressive Systemerkrankung. Z Rheumatol 2012;71:504-514.
16. Hill TG, Crawford JN, Rogers CC: Successful management of lichen myxedematosus. Arch Dermatol 1976;112:67-69.
17. Davis ML, Bartley GB, Gibson LE, Maguire LJ: Ophthalmic findings in scleromyxedema. Ophthalmology 1994;101:252-255.
18. Allen PW, Dymock RB, MacCormac LB: Superficial angiomyxomas with and without epithelial components. Report of 30 tumors in 28 patients. Am J Surg Pathol 1988;12:519-530.
19. Calonje E, Guerin D, McCormick D, Fletcher CD: Superficial angiomyxoma: Clinicopathologic analysis of a series of distinctive but poorly recognized cutaneous tumors with tendency for recurrence. Am J Surg Pathol 1999;23:910-917.
20. Allam M, Ghozzi M: Scleromyxedema: A case report and review of the literature. Case Rep Dermatol 2013;5:168-175.
21. Sansbury JC, Cocuroccia B, Jorizzo JL, Gubinelli E, Gisondi P, Girolomoni G: Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol 2004;51:126-131.
22. Migkou M, Gkotzamanidou M, Terpos E, Dimopoulos MA, Kastritis E: Response to bertezomib of a patient with scleromyxedema refractory to other therapies. Leuk Res 2011;35:209-211.
23. Bidier M, Zschoche C, Gholam P, Enk AH, Hadaschick EN: Scleromyxoedema: Clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes. Acta Derm Venereol 2012;92:339-409.
24. Jacob SE, Fien S, Kerdel FA: Scleromyxedema, a positive effect with thalidomide. Dermatology 2006;213:150-152.
25. Amini-Adle M, Thieulent N, Dalle S, Balme B, Thomas L: Scleromyxedema: Successful treatment with thalidomide in two patients. Dermatology 2007;214:58-60.
26. Efthimiou P, Blanco M: Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema. Case report and discussion of the literature. Semin Arthritis Rheum 2008;38:188-194.
27. Wright RC, Franco RS, Denton MD, Blaney DJ: Scleromyxedema. Arch Dermatol 1976;112:63-66.